Mini-MasterClass: mRNA PLATFORM

After participating in the Mini Masterclasses, learners will be able to:

• Recognize the rationale for mRNA-based vaccines and considerations for their design
• Discuss the effectiveness of mRNA-based vaccines to manage respiratory viral diseases based on clinical experiences with COVID-19 vaccines
• Describe recent developments in the use of the mRNA platform to develop prophylactic and therapeutic vaccines for respiratory diseases
• Translate mRNA platform technology in a means that patients can readily understand

Faculty Disclosures

• Dr.Wong has received honoraria from Stallergenes-Greer, Pfizer, Leo Pharma and has received funding from PHSA Medical Staff Association Engagement Funding.